Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257592 · ClinicalTrials.gov registry record · Phase 1
Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States
A Phase 1 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03257592: Clinical Trial Phase 1 study, sponsored by Johns Hopkins University.
NCT03257592 is a Phase 1 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03257592, a Phase 1 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Many neurological diseases, including AIDS dementia, Alzheimer's disease and schizophrenia, involve an inflammatory component thought to specifically involve glial cell activation. The Investigators has been concerned with the development of tools for noninvasive imaging of inflammatory processes in psychotic disease. Here, the investigators aim to use PET-based neuroimaging with carbon-11 N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo\[1,5-a\]pyrimidine-3-acetamide, (\[11C\]DPA)-713 to quantify regional distribution of translocator protein (TSPO), a putative marker of inflammation, in the brains of patients with schizophrenia and bipolar disorder, type I. The investigators will focus on patients in the early stages of disease (within first five years of onset of schizophrenia diagnosis and within first five years of first manis, respectively) to minimize the confounds of age-, chronic illness-, and medication- effects on our results.
Interventions
- DRUG [11C]DPA-713
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-08 |
| Est. Completion | 2018-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03257592
The ClinicalTrials.gov registry entry for NCT03257592 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]DPA-713 is the first listed.
NCT03257592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03257592 about?
NCT03257592 is a clinical study titled "Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States". Many neurological diseases, including AIDS dementia, Alzheimer's disease and schizophrenia, involve an inflammatory component thought to specifically involve glial cell activation. The Investigators has been concerned with the development of tools for noninvasive imaging of inflammatory processes in...
What is the current status of trial NCT03257592?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2010-08. Estimated completion is 2018-04.
What interventions are being tested in trial NCT03257592?
The interventions under investigation include: [11C]DPA-713 (DRUG).
Who is sponsoring clinical trial NCT03257592?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.